Woodline Partners LP Sells 279,282 Shares of Kenvue Inc. $KVUE

Woodline Partners LP decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 26.5% in the 1st quarter, Holdings Channel reports. The firm owned 773,866 shares of the company’s stock after selling 279,282 shares during the quarter. Woodline Partners LP’s holdings in Kenvue were worth $18,557,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. grew its position in shares of Kenvue by 4.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after buying an additional 4,034 shares during the period. IFP Advisors Inc grew its position in shares of Kenvue by 25.3% during the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock worth $369,000 after buying an additional 3,081 shares during the period. Vident Advisory LLC acquired a new stake in shares of Kenvue during the 1st quarter worth approximately $520,000. Starboard Value LP acquired a new stake in shares of Kenvue during the 4th quarter worth approximately $467,864,000. Finally, FORA Capital LLC acquired a new stake in shares of Kenvue during the 1st quarter worth approximately $981,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE KVUE opened at $18.46 on Thursday. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The company has a market cap of $35.42 billion, a P/E ratio of 24.94, a PEG ratio of 2.71 and a beta of 0.83. The company has a fifty day simple moving average of $21.23 and a 200 day simple moving average of $22.30. Kenvue Inc. has a 12-month low of $17.15 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.5%. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is presently 112.16%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Evercore ISI reduced their price objective on shares of Kenvue from $25.00 to $23.00 and set an “in-line” rating for the company in a research report on Monday. Royal Bank Of Canada reduced their price objective on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research report on Friday, August 8th. JPMorgan Chase & Co. reduced their price target on shares of Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, July 25th. UBS Group reduced their price target on shares of Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday, July 17th. Finally, Citigroup reduced their price target on shares of Kenvue from $24.50 to $22.00 and set a “neutral” rating for the company in a research report on Tuesday, July 15th. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $24.21.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.